Technical Analysis for BNTC - Benitec Biopharma Limited
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Very Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| NR7 | Range Contraction | 6.01% | |
| Narrow Range Bar | Range Contraction | 6.01% | |
| Upper Bollinger Band Walk | Strength | 6.01% | |
| Inside Day | Range Contraction | 6.01% | |
| Wide Bands | Range Expansion | 6.01% | |
| Slingshot Bullish | Bullish Swing Setup | 3.85% | |
| Wide Range Bar | Range Expansion | 3.85% | |
| Upper Bollinger Band Walk | Strength | 3.85% | |
| Wide Bands | Range Expansion | 3.85% |
| Alert | Time |
|---|---|
| Up 5% | about 13 hours ago |
| Rose Above Previous Day's High | about 14 hours ago |
| Up 3% | about 14 hours ago |
| Up 2% | about 14 hours ago |
| Up 1% | about 14 hours ago |
Get a Trading Assistant
- Earnings date: 05/13/2024
Benitec Biopharma Limited Description
Benitec Biopharma Limited, a biotechnology company, develops novel treatments for chronic and life-threatening conditions based on its gene silencing technology, DNA-directed RNA interference (ddRNAi). The company's ddRNAi technology provides novel therapeutics to treat a range of human medical diseases and conditions, such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer, and oculopharyngeal muscular dystrophy (OPMD). Its pipeline of in-house and partnered therapeutic programs include TT-034 for hepatitis C; Tribetarna for the treatment of chemotherapy resistant non-small cell lung cancer; Hepbarna for Hepatitis B; and Pabparna for the treatment of OPMD. The company also licenses its ddRNAi technology to biopharmaceutical companies for the clinical applications comprising HIV/AIDS, retinitis pigmentosa, and Huntington's disease. Benitec Biopharma Limited was founded in 1997 and is based in Sydney, Australia.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Biotechnology Biopharmaceutical Biology Pain Genetics Chemotherapy Genetic Engineering Hepatitis B Macular Degeneration Small Cell Lung Cancer Dystrophy Gene Expression Muscular Dystrophy Hepatitis C Huntington's Disease Wet Age Related Macular Degeneration HIV/Aids RNA Retinitis Rna Interference Ai Technology Clinical Applications Gene Silencing Retinitis Pigmentosa Chronic And Life Threatening Conditions Oculopharyngeal Muscular Dystrophy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 10.29 |
| 52 Week Low | 1.86 |
| Average Volume | 102,692 |
| 200-Day Moving Average | 3.83 |
| 50-Day Moving Average | 5.94 |
| 20-Day Moving Average | 7.04 |
| 10-Day Moving Average | 8.05 |
| Average True Range | 0.82 |
| RSI (14) | 66.56 |
| ADX | 57.12 |
| +DI | 36.73 |
| -DI | 8.26 |
| Chandelier Exit (Long, 3 ATRs) | 7.83 |
| Chandelier Exit (Short, 3 ATRs) | 7.21 |
| Upper Bollinger Bands | 9.63 |
| Lower Bollinger Band | 4.46 |
| Percent B (%b) | 0.81 |
| BandWidth | 73.29 |
| MACD Line | 0.85 |
| MACD Signal Line | 0.74 |
| MACD Histogram | 0.11 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.74 | ||||
| Resistance 3 (R3) | 9.66 | 9.21 | 9.55 | ||
| Resistance 2 (R2) | 9.21 | 8.93 | 9.25 | 9.49 | |
| Resistance 1 (R1) | 8.92 | 8.76 | 9.07 | 9.01 | 9.43 |
| Pivot Point | 8.48 | 8.48 | 8.55 | 8.52 | 8.48 |
| Support 1 (S1) | 8.19 | 8.20 | 8.34 | 8.27 | 7.85 |
| Support 2 (S2) | 7.75 | 8.03 | 7.79 | 7.79 | |
| Support 3 (S3) | 7.46 | 7.75 | 7.73 | ||
| Support 4 (S4) | 7.54 |
